Search

We performed a combination therapy with two drugs, 5'-DFUR and MMC, which proved to be markedly effective in one patient. The patient was 73-year-old female with tumor, advanced cancer gastric lower third portion. Borrmann type 3, an poorly differentiated adenocarcinoma. Since the patient rejected an operation, the drug therapy was selected. Oral administration of 5'-DFUR 800 mg daily was combined with intermittent intravenous administration of mitomycin C. In 3 years, the cancerous site got scarred and no distant metastasis was observed. Presently, she feels well, receiving an outpatient treatment.

Combinations of tobramycin (TOB) with cephalothin (CET) or carbenicillin (CBPC) were evaluated by in vitro test against 161 clinical isolates of Klebsiella pneumoniae, Escherichia coli, indole-positive Proteus, Enterobacter and Serratia marcescens which were not inhibited by 6.25 microgram/ml of CET. The combinations were considered to show synergy when there was a 4-fold or greater reduction in MIC values (FIC index less than or equal to 0.5) of both antibiotics when combined. Synergy of TOB with CET could be demonstrated against 83% of Klebsiella pneumoniae, 78% of E. coli, 44% of Proteus rettgeri and 39% of Proteus inconstans. Synergy of TOB with CBPC could be demonstrated against 78% of Proteus vulgalis, 45% of Serratia marcescens and 28% of Proteus inconstans. Bactericidal effect showing synergy of TOB with CET could be demonstrated against each 2 strains of Klebsiella pneumoniae and E. coli. Frequency of synergy of TOB with CET under the condition of large inoculum size was significantly higher than that of synergy of TOB with CET under the condition of small inoculum size. Synergy of bactericidal effect of TOB combined with CET against Klebsiella pneumoniae and E. coli was more active when they were combined at the same time, than those of when TOB was combined after 2 hours exposure by CET or when CET was combined after 2 hours exposure by TOB. No antagonistic action was observed in these studies.